JPH0560448B2 - - Google Patents
Info
- Publication number
- JPH0560448B2 JPH0560448B2 JP60221662A JP22166285A JPH0560448B2 JP H0560448 B2 JPH0560448 B2 JP H0560448B2 JP 60221662 A JP60221662 A JP 60221662A JP 22166285 A JP22166285 A JP 22166285A JP H0560448 B2 JPH0560448 B2 JP H0560448B2
- Authority
- JP
- Japan
- Prior art keywords
- ibuprofen
- analgesic
- chlorphenesin carbamate
- carbamate
- muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960004878 chlorphenesin carbamate Drugs 0.000 claims description 27
- SKPLBLUECSEIFO-UHFFFAOYSA-N chlorphenesin carbamate Chemical compound NC(=O)OCC(O)COC1=CC=C(Cl)C=C1 SKPLBLUECSEIFO-UHFFFAOYSA-N 0.000 claims description 27
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 24
- 229960001680 ibuprofen Drugs 0.000 claims description 24
- 230000000202 analgesic effect Effects 0.000 claims description 20
- 239000004480 active ingredient Substances 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 230000002195 synergetic effect Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000002040 relaxant effect Effects 0.000 description 8
- 230000007059 acute toxicity Effects 0.000 description 7
- 231100000403 acute toxicity Toxicity 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- UKNGDQSYPNBJAO-UHFFFAOYSA-N Tiaramide hydrochloride Chemical compound Cl.C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 UKNGDQSYPNBJAO-UHFFFAOYSA-N 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003158 myorelaxant agent Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 241000978776 Senegalia senegal Species 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical compound OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- -1 sedative-hypnotics Substances 0.000 description 2
- 208000005801 spondylosis Diseases 0.000 description 2
- HTJXMOGUGMSZOG-UHFFFAOYSA-N tiaramide Chemical compound C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 HTJXMOGUGMSZOG-UHFFFAOYSA-N 0.000 description 2
- 229950010302 tiaramide Drugs 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000007103 Spondylolisthesis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60221662A JPS6281311A (ja) | 1985-10-04 | 1985-10-04 | 鎮痛剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60221662A JPS6281311A (ja) | 1985-10-04 | 1985-10-04 | 鎮痛剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6281311A JPS6281311A (ja) | 1987-04-14 |
JPH0560448B2 true JPH0560448B2 (hu) | 1993-09-02 |
Family
ID=16770292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP60221662A Granted JPS6281311A (ja) | 1985-10-04 | 1985-10-04 | 鎮痛剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6281311A (hu) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260337A (en) * | 1992-07-29 | 1993-11-09 | Merck & Co., Inc. | Ibuprofen-muscle relaxant combinations |
-
1985
- 1985-10-04 JP JP60221662A patent/JPS6281311A/ja active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS6281311A (ja) | 1987-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Muir et al. | Comparative bioavailability of aspirin and paracetamol following single dose administration of soluble and plain tablets | |
JPH0717501B2 (ja) | 高めた無痛覚を与える製薬製品 | |
US4888343A (en) | Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process | |
CA3101274A1 (en) | Use of neutrophil elastase inhibitors in liver disease | |
JP3122748B2 (ja) | イブプロフェン含有解熱鎮痛剤 | |
JP2704721B2 (ja) | イブプロフエン製剤 | |
EP0190851B1 (en) | Improved antiinflammatory composition | |
JPH0140009B2 (hu) | ||
HU228051B1 (en) | A pharmaceutical composition for the treatment of autoimmune diseases | |
JPH05246845A (ja) | イブプロフェン含有解熱鎮痛剤 | |
RU2203047C2 (ru) | Композиция для снижения содержания церамидов | |
HU193845B (en) | Process for preparing synergic pharmaceutical preparations comprising flupyrthine and 4-acetamido-phenol | |
JP3982889B2 (ja) | イブプロフェン含有医薬製剤 | |
JPH0560448B2 (hu) | ||
JPS648602B2 (hu) | ||
EP0218453A1 (en) | Improved antiinflammatory compositions and methods | |
EP0059031B1 (en) | Analgesic and anti-inflammatory composition | |
JP2000344665A (ja) | 鎮痛剤 | |
JP2000080034A (ja) | 風邪用組成物 | |
Azarnoff et al. | Therapeutic implications of bioavailability | |
JPS6293230A (ja) | 組合せ製剤 | |
JPS5942318A (ja) | 製薬組成物、その製造法及び応用 | |
JPH09227371A (ja) | 粥状動脈硬化抑制剤 | |
JP2005289905A (ja) | 医薬組成物 | |
RU2174836C1 (ru) | Фармацевтическая композиция, обладающая анальгезирующим действием |